Annals of hepatology · 2025
Fenofibrate in managing cholestatic pruritus in paediatric patients.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Quintero-Bernabeu Jesús, Juamperez-Goñi Javier, Padrós-Fornieles Cristina, Larrarte-King Mauricio, Mameli Simone, Vidal-Valdivia Lis, Clemente-Bautista Susana, Fernández-Polo Aurora, Molino-Gahete José Andrés, Mercadal-Hally Maria
Аннотация
INTRODUCTION AND OBJECTIVES: Cholestatic pruritus is a difficult-to-manage symptom in cholestatic disorders. This study presents our experience with fenofibrate for treating refractory cholestatic pruritus in paediatric patients.
MATERIALS AND METHODS: We conducted a retrospective review involving patients under 18 with moderate to severe pruritus (5D Itch score >15), unresponsive to conventional treatments. Fenofibrate was administered at 100 mg/20 kg daily, with a maximum dose of 100 mg for those under 20 kg. A good response was defined as a >50% reduction in the 5D Itch score, with partial relief as a 25-50% reduction.
RESULTS: Between May 2017 and May 2023, 25 patients were treated, with a median treatment duration of 24.2 months. Pruritus reduction at 2 weeks, 1, 3, 6, and 12 months was 36.8%, 52.2%, 53.6%, 57.1%, and 60.8%, respectively. After 12 months, 64% (16/25) achieved >50% improvement, and 16% (4/25) showed partial relief. Fenofibrate significantly reduced serum bile acids, AST, ALT, bilirubin, cholesterol, and triglycerides, without affecting elastography. No serious adverse events occurred.
CONCLUSIONS: Fenofibrate shows potential in managing pruritus in paediatric patients with cholestatic diseases, warranting further investigation through randomized clinical trials to assess its efficacy and safety.
MATERIALS AND METHODS: We conducted a retrospective review involving patients under 18 with moderate to severe pruritus (5D Itch score >15), unresponsive to conventional treatments. Fenofibrate was administered at 100 mg/20 kg daily, with a maximum dose of 100 mg for those under 20 kg. A good response was defined as a >50% reduction in the 5D Itch score, with partial relief as a 25-50% reduction.
RESULTS: Between May 2017 and May 2023, 25 patients were treated, with a median treatment duration of 24.2 months. Pruritus reduction at 2 weeks, 1, 3, 6, and 12 months was 36.8%, 52.2%, 53.6%, 57.1%, and 60.8%, respectively. After 12 months, 64% (16/25) achieved >50% improvement, and 16% (4/25) showed partial relief. Fenofibrate significantly reduced serum bile acids, AST, ALT, bilirubin, cholesterol, and triglycerides, without affecting elastography. No serious adverse events occurred.
CONCLUSIONS: Fenofibrate shows potential in managing pruritus in paediatric patients with cholestatic diseases, warranting further investigation through randomized clinical trials to assess its efficacy and safety.